Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · OCUL · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
29
12 Months
Buy/Sell ratio
0.03
Buy/Sell (by trades)
Overall sentiment
Ocular Therapeutix, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
OCUL insider buying and selling by quarter
OCUL insider selling · OCUL insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · OCUL ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
OCUL executive sell shares · OCUL board member insider trading · OCUL insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 3, 2026 | Waheed Nadia Chief Medical Officer | Sale | 14,828 | $123K | Form 4 |
| May 26, 2026 | Dugel Pravin See Remarks · Director | Sale | 21,156 | $173K | Form 4 |
| May 28, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| May 28, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| May 26, 2026 | Kaiser Peter Chief Development Officer | Sale | 2,967 | $24K | Form 4 |
| May 26, 2026 | Heier Jeffrey S. Chief Scientific Officer | Sale | 3,018 | $25K | Form 4 |
| May 26, 2026 | Nayak Sanjay Chief Strategy Officer | Sale | 1,858 | $15K | Form 4 |
| Apr 9, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| Apr 9, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| Feb 23, 2026 | Dugel Pravin See Remarks · Director | Sale | 20,056 | $166K | Form 4 |
| Feb 23, 2026 | Kaiser Peter Chief Development Officer | Sale | 2,810 | $23K | Form 4 |
| Feb 23, 2026 | Heier Jeffrey S. Chief Scientific Officer | Sale | 3,057 | $25K | Form 4 |
| Feb 23, 2026 | Nayak Sanjay Chief Strategy Officer | Sale | 1,759 | $15K | Form 4 |
| Feb 20, 2026 | Waheed Nadia Chief Medical Officer | Sale | 3,510 | $27K | Form 4 |
| Feb 20, 2026 | LINDSTROM RICHARD L MD Director | Purchase | 60,229 | $461K | Form 4 |
| Feb 12, 2026 | Notman Donald COO | Sale | 11,446 | $103K | Form 4 |
| Feb 12, 2026 | Nayak Sanjay Chief Strategy Officer | Sale | 10,348 | $94K | Form 4 |
| Feb 12, 2026 | Dugel Pravin See Remarks · Director | Sale | 124,882 | $1.13M⚡ | Form 4 |
| Feb 12, 2026 | Waheed Nadia Chief Medical Officer | Sale | 7,863 | $71K | Form 4 |
| Feb 2, 2026 | Notman Donald COO | Sale | 5,455 | $50K | Form 4 |
| Feb 4, 2026 | Notman Donald COO | Sale | 6,035 | $52K | Form 4 |
| Jan 21, 2026 | Robinson David Wayne Global CCO | Award | 136,000 | — | Form 4 |
| Jan 2, 2026 | Anderman Todd Chief Legal Officer | Award | 64,900 | — | Form 4 |
| Jan 2, 2026 | Meyers Steve Lawrence Chief Commercial Officer | Award | 64,900 | — | Form 4 |
| Jan 2, 2026 | Nayak Sanjay Chief Strategy Officer | Award | 64,900 | — | Form 4 |
Waheed Nadia
Chief Medical Officer
Date
Jun 3
Shares
14,828
Price
$8.27
Value
$123K
Dugel Pravin
See Remarks · Director
Date
May 26
Shares
21,156
Price
$8.20
Value
$173K
Kaiser Peter
Chief Development Officer
Date
May 26
Shares
2,967
Price
$8.20
Value
$24K
Heier Jeffrey S.
Chief Scientific Officer
Date
May 26
Shares
3,018
Price
$8.20
Value
$25K
Nayak Sanjay
Chief Strategy Officer
Date
May 26
Shares
1,858
Price
$8.20
Value
$15K
Dugel Pravin
See Remarks · Director
Date
Feb 23
Shares
20,056
Price
$8.28
Value
$166K
Kaiser Peter
Chief Development Officer
Date
Feb 23
Shares
2,810
Price
$8.28
Value
$23K
Heier Jeffrey S.
Chief Scientific Officer
Date
Feb 23
Shares
3,057
Price
$8.28
Value
$25K
Nayak Sanjay
Chief Strategy Officer
Date
Feb 23
Shares
1,759
Price
$8.28
Value
$15K
LINDSTROM RICHARD L MD
Director
Date
Feb 20
Shares
60,229
Price
$7.66
Value
$461K
Nayak Sanjay
Chief Strategy Officer
Date
Feb 12
Shares
10,348
Price
$9.04
Value
$94K
Dugel Pravin
See Remarks · Director
Date
Feb 12
Shares
124,882
Price
$9.04
Value
$1.13M ⚡
Meyers Steve Lawrence
Chief Commercial Officer
Date
Jan 2
Shares
64,900
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About OCUL insider trading
OCUL insider trades
Ocular Therapeutix, Inc. (OCUL) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Dugel Pravin (See Remarks · Director), Kaiser Peter (Chief Development Officer), Heier Jeffrey S. (Chief Scientific Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. OCUL insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Ocular Therapeutix, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
OCUL insider trading · 5 questionsThe insiders of Ocular Therapeutix, Inc. (OCUL) include executives and directors such as Dugel Pravin (See Remarks · Director), Kaiser Peter (Chief Development Officer), Heier Jeffrey S. (Chief Scientific Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026